Premium
Lipoprotein(a) enhances plasma clot lysis in vitro
Author(s) -
Mao Simon J.T.,
Tucci Michelle A.
Publication year - 1990
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(90)80306-4
Subject(s) - plasmin , fibrinolysis , lysis , streptokinase , chemistry , lipoprotein(a) , fibrinogen , plasminogen activator , biochemistry , in vitro , fibrin , tissue plasminogen activator , microbiology and biotechnology , lipoprotein , immunology , biology , enzyme , medicine , endocrinology , cholesterol , myocardial infarction
Human plasma lipoprotein(a) (Lp(a)) is a macromolecular complex that contains a protein homologous to plasminogen, the precursor of plasmin. We confirmed recent reports that Lp(a) is not activated by streptokinase or tissue plasminogen activator (t‐PA) to yield plasmin‐like activity. In testing the hypothesis that Lp(a) can competitively inhibit plasma clot lysis mediated by plasmin, the present study shows that Lp(a) significantly enhanced plasma clot lysis mediated by streptokinase or t‐PA. The enhancement, however, was not observed in a plasmin‐mediated clot lysis using a purified fibrinogen system. The addition of α‐ 2 ‐antiplasmin (α 2 ‐plasmin inhibitor) to this system inhibited fibrinolysis; however, no inhibition was observed in the presence of Lp(a). One potential explanation for the Lp(a)‐enhanced plasma clot lysis is that Lp(a) neutralizes the activity of α 2 ‐antiplasmin present in plasma, thereby restoring the activity of plasmin to lyse the clot.